MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
MaxCyte, Inc.NASDAQ: MXCT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $9.65M fell 7.1% year over year, ahead of the -14.3% change in trailing-twelve-month revenue. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $34.08M (+3.2%) for the fiscal year ending Dec 2026, a step up from the -14.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.65M+32.2% QoQ
- Last fiscal yearDec 2025
- $33.03M-14.5% YoY
- LTMMar 2026
- $32.29M-14.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.1% | -23.5% | -16.4 pp |
| 1 year | -14.5% | +3.2% | +17.7 pp |
| 3-year CAGR | -9.3% | +20.3% | +29.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 33.03M USD
- Year-over-year change
- -14.5%
- 4-year CAGR
- -0.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.03M | -14.5% |
| FY2024 | 2024-12-31 | 38.63M | -6.4% |
| FY2023 | 2023-12-31 | 41.29M | -6.7% |
| FY2022 | 2022-12-31 | 44.26M | +30.6% |
| FY2021 | 2021-12-31 | 33.89M | — |
Revenue vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 revenue of $32.29M is the 6th highest of the 11 companies compared; the peer median is $26.71M.
- Its year-over-year change of -14.3% is the 7th highest of 11, against a peer median of +8.3%.
- Over three fiscal years its annual growth of -9.3% compares with a peer median of +15.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $113.75M | +174.0% | +91.5% | |
| LTM Mar 2026 | $107.06M | +26.8% | +15.2% | |
| LTM Mar 2026 | $57.7M | +1.1% | +18.2% | |
| LTM Mar 2026 | $44.88M | +39.6% | +53.9% | |
| LTM Mar 2026 | $34.56M | -45.8% | -29.2% | |
| LTM Mar 2026 | $32.29M | -14.3% | -9.3% | |
| LTM Mar 2026 | $18.87M | +34.8% | +34.8% | |
| LTM Dec 2025 | $13.02M | +15.4% | +14.9% | |
| LTM Mar 2026 | $2.96M | -37.1% | -3.8% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.85M | -25.7% | -15.8% |
| LTM Mar 2026 | $618K | -58.0% | -50.1% | |
| Peer median (excluding MXCT) | $26.71M | +8.3% | +15.0% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Cost of Revenue | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| Gross Profit | 30.25M | 39.16M | 36.55M | 31.53M | 26.8M |
| Gross Margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Research & Development | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| Selling, General & Admin | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| Operating Expenses | 48.44M | 66.52M | 84.85M | 82.72M | 72.09M |
| Depreciation & Amortization | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M |
| EBITDA | (16.61M) | (20.75M) | (33.75M) | (36.27M) | (39.49M) |
| EBITDA Margin | -49.0% | -46.9% | -81.7% | -93.9% | -119.6% |
| Operating Income | (18.19M) | (27.36M) | (48.3M) | (51.2M) | (45.29M) |
| Operating Margin | -53.7% | -61.8% | -117.0% | -132.5% | -137.1% |
| Interest Income | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income / Expenses | (893.6K) | 3.79M | 10.38M | 10.14M | 655K |
| Income Before Tax | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Pre-Tax Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Net Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (Basic) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| EPS (Diluted) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| Weighted Avg Shares | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Weighted Avg Shares (Diluted) | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.